Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

Inclusion Criteria:

• 18-75 years, all genders

• Patients with definite B-cell Lymphoma, includes FL, MZL, MCL, DLBCL.

• Patients With Relapsed or Refractory B-cell Lymphoma

• ECOG ≤ 2

• Lesions are measurable in 21 days before treatment

• Normal bone marrow function

• Normal liver, kidney, lung and heart function

• the Subjects can sign the ICF and obey the protocol, elsewise, his/her guardian shouldsign

• Life expectancy is at least 3 months

Exclusion Criteria:• Past or present CNS disease

• Associated with lymphoma by the infiltrates of CNS

• A history of autoimmune disease with CNS involvement or autoimmune disease

• Previous history of autoimmune disease or other malignancy

• A history of deep venous thrombosis or pulmonary embolism

• Auto-HSCT was performed within 12 weeks prior to initiation of treatment

• Previous organ transplantation or allogeneic hematopoietic stem cell transplantation

• The Investigator determined that the patients were associated with a disease, medicalcondition, or social factor that might affect study results or compliance

• Immunosuppressant are being used

• Radiotherapy was given within 6 weeks prior to A-319 treatment

• Chemotherapy, immunotherapy and targeted therapy were received within 4 weeks beforeA-319 treatment

• Previous CAR-T cell therapy

• Received anti-lymphoma drugs in the first 4 weeks of A-319 treatment

• There was no recovery of toxic effects (CTCAE> grade 1 adverse events) at the lasttreatment, except hair loss

• Those who underwent major surgery 28 days before enrollment (excluding lymph nodebiopsy);Or plan to operate during the study period

• Those who had received active/attenuated live vaccine within 28 days prior toscreening

• For pregnant (positive pregnancy test) and lactating women, those of childbearing agewho signed the informed consent form and did not agree to use contraception for atleast 3 months after the end of the study;Within 7 days prior to the first day oftreatment, women of childbearing age require a positive serum pregnancy test (HCG)

• Male patients who signed informed consent forms and did not agree to use contraceptionfor at least 3 months at the end of the study (except surgical sterilization)

• Known allergy to immunoglobulin or research drugs and their excipients

• Patients considered unfit to participate in the study